Tagged with GCC

Saudi Arabia Marwan Omar, General Manager of Ferring in the GCC, lays out the company’s growth strategy and its deep commitment to the region. With a focus on local talent development, strategic partnerships, and expanding its product portfolio, Ferring continues to strengthen its presence in reproductive medicine, gastroenterology, and uro-oncology.   Investing…

Saudi Arabia AstraZeneca has made remarkable progress over the past three years in Saudi Arabia, gaining significant leadership in therapeutic areas like oncology and respiratory care, and expansion into rare diseases. Sameh ElFangary, Country President of AstraZeneca GCC & Pakistan shares insights into the company’s strategy and strong alignment with Saudi Arabia’s…

Saudi Arabia If the number of strategic deals and industry announcements coming out of the recent CPHI Middle East in Riyadh are anything to go by, Saudi Arabia’s ambition to become a regional and global innovation hub is becoming a reality. Read on for some highlights from the first regional edition of…

Saudi Arabia Simona Grandits, VP of EEMEA at QIAGEN, reflects on the evolution of the German company whose revenues are now split between life sciences and molecular diagnostics, and the growing importance of bioinformatics for which QIAGEN is developing a data centre in Saudi Arabia. Grandits also reviews QIAGEN’s preventive healthcare initiatives…

UAE Sanofi’s Preeti Futnani explores the rapid healthcare transformation underway in the UAE and Saudi Arabia, where governments are increasingly prioritising innovation and how Sanofi is leveraging its strong relationships and pipeline of breakthrough medications to align with regional goals. She touches on how Sanofi GCC is integrating digital tools to…

Saudi Arabia Saudi Arabia has made major progress on the road to implementing the healthcare reforms set out in its Vision 2030. Assistant Minister of Health Dr Mohammed Alabdulaali speaks to PharmaBoardroom about that progress and plans to further pursue the Kingdom’s digital transformation, integrate preventive care and expand healthcare infrastructure. Additionally,…

Saudi Arabia After various leadership roles at Takeda over the course of ten years, Khaled Sary has taken on the position of general manager for the West Gulf cluster, which encompasses Saudi Arabia, Qatar, Oman and Bahrain. In conversation with PharmaBoardroom, Sary discusses the significant growth the Japanese pharma has seen in…

Saudi Arabia Established as one of the initiatives launched by the Ministry of Health within Saudi Arabia’s Vision 2030, the Saudi National Institute for Health (Saudi NIH) aims to strengthen the Kingdom’s biomedical research landscape, funding high impact research and enhancing alignment with regulatory bodies. CEO and former academic Prof Fars Alanazi…

Saudi Arabia SAJA Pharmaceuticals is aiming to grow from a regional player to a multinational entity, in line with Saudi Arabia’s Vision 2030, leveraging strong partnerships, technology transfer, and strategic licensing to expand geographically. CEO Mohammed Khalil explains how the Saudi firm prides itself on its agility and commitment to high-quality, accessible…

Saudi Arabia As a part of the sweeping transformation Saudi Arabia is achieving thanks to its Vision 2030, the Kingdom is also advancing its research ambitions. With the restructuring of its regulatory framework along with its well-established network of research institutes and bolstered by the integration of electronic health records, Saudi has…

Saudi Arabia PwC veteran of 20 years and partner in the consulting firm’s strategy arm, Strategy&, Dr Walid Tohme has been directly involved in Saudi Arabia’s healthcare transformation journey since 2016. He discusses the significant progress that has been made since then, including the institutional restructuring to separate regulatory functions from healthcare…

Saudi Arabia Faisal Al Tlasi introduces Axantia’s strategic goals, the transformation of Saudi Arabia’s healthcare system, and the company’s role in supporting Vision 2030. He discusses the importance of expanding the company’s product portfolio, entering new markets, and enhancing employee capabilities. Emphasizing partnerships and regulatory advancements, Al Tlasi underscores Axantia’s commitment to…